SPAS(SH:603168)2021-10-29 16:00Financial Performance - The company's operating revenue for Q3 2021 was ¥156,368,821.41, representing a year-on-year increase of 52.37%[3] - The net profit attributable to shareholders for the same period was ¥9,191,599.10, with a year-to-date net profit of ¥36,146,960.68[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was ¥10,335,319.00, with a year-to-date figure of ¥35,641,147.21[3] - The basic earnings per share for Q3 2021 was ¥0.03, with a year-to-date figure of ¥0.11[3] - The net profit for the third quarter of 2021 was CNY 36,146,960.68, a significant recovery from a net loss of CNY 28,056,470.86 in the same period of 2020, marking a turnaround of over 228%[23] - Operating profit for the third quarter was CNY 47,093,345.56, compared to an operating loss of CNY 53,040,421.59 in the previous year, indicating a positive shift in operational performance[23] Revenue Growth - The company attributed the revenue growth to the addition of new medical segment businesses and increased sales of eye drops and cephalosporins[7] - The year-to-date operating revenue increased by 96.97% compared to the same period last year, driven by similar factors[7] - Total operating revenue for the first three quarters of 2021 reached ¥473,106,190.73, a significant increase from ¥240,193,945.35 in the same period of 2020, representing a growth of approximately 96.7%[22] - Total revenue from sales of goods and services received in the first three quarters of 2021 reached CNY 494,360,195.78, compared to CNY 269,193,229.97 in the previous year, reflecting an increase of about 83.6%[26] Cash Flow and Assets - The cash flow from operating activities for the year-to-date period was ¥42,341,400.32, showing an increase of 84.41%[3] - Cash flow from operating activities for the first three quarters of 2021 was CNY 42,341,400.32, up from CNY 22,959,883.89 in the same period of 2020, representing an increase of approximately 84%[26] - The cash and cash equivalents at the end of the reporting period stood at CNY 151,671,066.56, down from CNY 382,446,373.65 at the end of the previous year, indicating a decrease of approximately 60.3%[27] - The company recorded a net cash inflow from investing activities of CNY 2,549,093.06, a significant drop from CNY 139,545,699.76 in the previous year, showing a decrease of about 98.2%[27] - The total cash outflow from operating activities was CNY 483,508,952.38, compared to CNY 259,789,659.17 in the previous year, reflecting an increase of approximately 86.4%[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,507,964,709.88, a decrease of 9.86% compared to the end of the previous year[4] - As of September 30, 2021, total assets amounted to ¥1,507,964,709.88, down from ¥1,672,903,308.03 at the end of 2020, a decrease of about 9.8%[19] - The total liabilities reached CNY 370.48 million, with current liabilities at CNY 361.92 million and non-current liabilities at CNY 8.57 million[32] - Current liabilities decreased significantly to ¥161,201,238.65 from ¥361,918,221.00, a reduction of approximately 55.5%[19] Shareholder Information - The total number of common shareholders at the end of the reporting period was 19,921[9] - The largest shareholder, Chen Dekang, holds 52,572,504 shares, representing 16.30% of the total shares[9] - The total equity attributable to shareholders rose to ¥1,342,265,524.90 from ¥1,306,118,564.22, an increase of about 2.8%[19] Research and Development - Research and development expenses surged to ¥80,225,354.08 in the first three quarters of 2021, up from ¥14,659,276.24 in 2020, reflecting an increase of approximately 447.5%[22] - The company is focusing on market expansion and new product development, as indicated by the significant increase in R&D expenses[22] - The company has initiated a consistency evaluation for the benzalkonium chloride eye drops, with clinical trials currently underway[10] - The company has completed the recruitment of participants for the clinical trial of benzalkonium chloride eye drops and aims to expedite the process[10] Investment and Financial Management - The company plans to use up to 500 million RMB of idle funds for entrusted wealth management, which is 33.58% of the audited net assets as of December 31, 2019[11] - The company has committed to investing in low-risk, short-term financial products through entrusted wealth management[12] - The company has not reported any overdue principal or interest from its entrusted wealth management activities[12] Equity Transfer and Subsidiary Sale - The company adjusted the listing price for the 100% equity transfer of Qiangshen Pharmaceutical to 82 million RMB[14] - As of September 30, 2021, the company received 41.82 million RMB as the first payment for the equity transfer from Yue's Pharmaceutical[15] - The company has been actively pursuing the sale of its subsidiary, Qiangshen Pharmaceutical, with the process ongoing[13]